Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-12-25
2009-10-27
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S816000
Reexamination Certificate
active
07608636
ABSTRACT:
A medicament for therapeutic and/or prophylactic treatment of neuropathic pain, which comprises a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:wherein R1represents a hydrogen atom or a hydroxyl group; R2represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; R3represents a phenyl group which may have 1 to 3 atoms or substituents selected from the group consisting of a halogen atom, a hydroxyl group, an alkyl group having 1 to 3 carbon atoms, and an alkoxyl group having 1 to 3 carbon atoms, or represents —NH—R4wherein R4represents a phenyl group which may have 1 to 3 atoms or substituents selected from the group consisting of a halogen atom, a hydroxyl group, an alkyl group having 1 to 3 carbon atoms, and an alkoxyl group having 1 to 3 carbon atoms or hydrogen atom, and n represents 0 or 1.
REFERENCES:
patent: 3459738 (1969-08-01), Morren
patent: 4118396 (1978-10-01), Pifferi et al.
patent: 4341790 (1982-07-01), Betzing et al.
patent: 4369139 (1983-01-01), Kyburz et al.
patent: 4431641 (1984-02-01), Mondadori et al.
patent: 4620973 (1986-11-01), Truog
patent: 4696943 (1987-09-01), Gobert et al.
patent: 4837223 (1989-06-01), Gobert et al.
patent: 4943639 (1990-07-01), Gobert et al.
patent: 5232700 (1993-08-01), Centifanto
patent: 5551846 (1996-09-01), Taylor et al.
patent: 5885976 (1999-03-01), Sandyk
patent: 5886023 (1999-03-01), Otomo et al.
patent: 5919803 (1999-07-01), Giblin et al.
patent: 6107330 (2000-08-01), Nabeshima et al.
patent: 6281242 (2001-08-01), Regan et al.
patent: 6365621 (2002-04-01), Tanaka et al.
patent: 6399650 (2002-06-01), Otomo et al.
patent: 6417220 (2002-07-01), Yoshii et al.
patent: 6423739 (2002-07-01), Otomo et al.
patent: 2004/0077709 (2004-04-01), Murashima et al.
patent: 1288347 (1991-09-01), None
patent: 0 243 336 (1987-10-01), None
patent: 0408524 (1991-01-01), None
patent: 1 020 189 (2000-07-01), None
patent: 42-19093 (1967-09-01), None
patent: 52-23072 (1977-02-01), None
patent: 54-117468 (1979-09-01), None
patent: 56-2960 (1981-01-01), None
patent: 60-252461 (1985-12-01), None
patent: 61-280470 (1986-12-01), None
patent: 62-5404 (1987-02-01), None
patent: 3-048657 (1991-03-01), None
patent: 3-46466 (1991-07-01), None
patent: 4-160496 (1992-06-01), None
patent: 04219093 (1992-08-01), None
patent: 5-163144 (1993-06-01), None
patent: 5-163145 (1993-06-01), None
patent: 6-65197 (1994-03-01), None
patent: WO 97/06319 (1997-02-01), None
patent: 98/14213 (1998-04-01), None
patent: WO 98/14213 (1998-04-01), None
patent: 00/07593 (2000-02-01), None
patent: WO 00/07593 (2000-02-01), None
patent: 00/72844 (2000-12-01), None
patent: WO 00/72844 (2000-12-01), None
patent: WO 00/78244 (2000-12-01), None
patent: WO 01/39779 (2001-06-01), None
Ubels et al. “Walking training for intermittent Claudication in diabetes,” Diabetes care, 1999, vol. 22, No. 2, pp. 198-201.
Gouliaev et al. “Piracetam and other structurally related nootropics,” Brain Research Review, 1994, vol. 19, pp. 180-222.
Hitzenberger et al. “Pharmacological properties of piracetam, rational for use in stroke patients,” CNS Drug; 1998, vol. 9, suppl 1, pp. 19-27.
Glas-Schottl “Piracetam in the treatment of soft tissue rheumatism,” Fortschritte der Medizin, 1989, vol. 107, No. 13, pp. 298-302.
The Merck Manual, fifteenth edition, pp. 1380-1387.
“Carpal tunnel syndrome” Wikipedia, http://en.wikipedia.org/wiki/Carpal—tunnel—syndrome.
Danilova et al. “The effect of piracetam and its combination with sodium hydroxybutyrate in neuropathic pain syndrom,” Eksperimental' naya i Klinicheskaya Farmakologiya (1996), vol. 59, No. 4, pp. 8-10, CAPLUs Abstract.
Gwak et al. “Activation of spinal GABA receptors attenuates chronic ventral neuropathic pain after spinal cord injury,” Journal of Neurotrauma, 2006, vol. 23, pp. 1111-1124.
Rashid et al. “Nonopioid and neuropathy-specific analgesic action of the nootropic drug nefiractem in mice,” The Journal of Pharmacology and experimental therapeutics, 2002, vol. 303, No. 1, pp. 226-231.
English Language Abstracts JP3-48657.
Hirato, M., Igaku no Ayumi, vol. 195, No. 9, 2000, 12.2, pp. 627-632 , 2000.
Ye, X. et al., “Botulinum Toxin C3 Inhibits Hyperalgesia in Mice with Partial Sciatic Nerve Injury,”Jpn. J. Pharmacol., vol. 83, pp. 161-163.
Malmberg, A.B., “Partial Sciatic Nerve Injury in the Mouse as a Model of Neuropathic Pain: Behavioral and Neuroanatomical Correlates,”Pain, vol. 76, pp. 215-222 , 1998.
Database Medline ′Online! US National Library of Medicine (NLM), Bethesda, MD, US ; Jul. 1996, Danilova E I et al.: “The action of piracetam and its complex with sodium oxybutyrate in the neuropathic pain syndrome!”; XP002361863; Database accession No. NLM9026199 & Eksperimental 'Naia I Klinicheskaia Farmakologiia. Jul.-Aug. 1996, vol. 59, No. 4, Jul. 1996, pp. 8-10, ISSN: 0869-2092.
Kitano Y et al.: “General Pharmacological Profile of the New Cognition-Enhancing Agent Nefiracetam Allgemeines Pharmakologisches Profil Des Neuen Nootropikums Nefiracetam” Arzneimittel Forschung. Drug Research, ECV Editio Cantor Verlag, Aulendorf, DE, vol. 44, No. 2A, Feb. 1994, pp. 199-210, XP001073794, ISSN: 0004-4172.
Chong M S et al.: “Anticonvulsants for the Management of Pain” Pain Reviews, Arnold, London, GB, vol. 7, No. 3/4, 2000, pp. 129-149, XP008016567, ISSN: 0968-1302, p. 139, right-hand column, paragraph 2.
Nabeshima T: “Ameliorating Effects of Nefiracetam (DM-9384) on Brain Dysfunction” Drugs of Today / Medicamentos De Actualidad, J.R. Prous SS.A. International Publishers, ES, vol. 30, No. 5, Jul. 1994, pp. 357-379, XO001034923, ISSN: 0025-7656.
Ardid D et al.: “Levetiracetam (keppra), a new antiepileptic drug, is effective in neuropathic but not acute pain models in rats”, Neurology, vol. 56, No. 8 Supplement 3, Apr. 24, 2001(Nov. 1, 2001), pp. A350-A351, XP008057865 & 53rdAnnual Meeting of the American Academy of Neurology; Philadelphia, PA, USA; May 5-11, 2001, issn: 0028-3878.
Aiken S.P. et al.: “Treatment of epilepsy: existing therapies and future developments” Frontiers in Bioscience, No. 5, Nov. 1, 2000, pp. E124-E152, XP002361861, p. 127 paragraph 2.5,6 and p. 137 paragraph 4.2.8.
Kongetsu no Chiryo (Treatment of this Month), vol. 8, No. 3, 2000, Separate Issue, pp. 56-61.
Rashid et al., “Nonopoid and Neuropathy-Specific Analgesic Action of the Nootropic Drug Nefiracetam in Mice,” The Journal of Pharmacology and Experimental Therapeutics, vol. 303(1), 226-31 (2002).
Tomikawa Munehiro
Ueda Hiroshi
Hamilton Pharmaceuticals, Inc.
Howrey LLP
Wang Shengjun
LandOfFree
Medicines for treatment and prevention of neurogenic pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicines for treatment and prevention of neurogenic pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicines for treatment and prevention of neurogenic pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4127771